Albadri Z, Almousali R, Abdulla S
Glob Cardiol Sci Pract. 2025; 2024(6):e202453.
PMID: 40026588
PMC: 11871560.
DOI: 10.21542/gcsp.2024.53.
Chen A, Lu D, Yang Z, Che X, Xia Y, Shao X
Heliyon. 2023; 9(8):e19269.
PMID: 37654461
PMC: 10466922.
DOI: 10.1016/j.heliyon.2023.e19269.
Hsieh I, Chen C, Hsieh M, Yang C, Chen D, Chang S
PLoS One. 2015; 10(9):e0138512.
PMID: 26406989
PMC: 4583430.
DOI: 10.1371/journal.pone.0138512.
Wang L, Mao S, Qi J, Ren Y, Guo X, Chen K
Chin J Integr Med. 2015; 21(9):662-6.
PMID: 26142341
DOI: 10.1007/s11655-015-2284-1.
Versaci F, Reimers B, Prati F, Gaspardone A, Del Giudice C, Pacchioni A
Mayo Clin Proc. 2012; 87(1):50-8.
PMID: 22212968
PMC: 3498377.
DOI: 10.1016/j.mayocp.2011.10.002.
Appraisal of the prognosis in patients with acute myocardial infarction treated with primary percutaneous coronary intervention.
Ma X, Yin H, Chen K
Chin J Integr Med. 2009; 15(3):236-40.
PMID: 19568720
DOI: 10.1007/s11655-009-0236-3.
Response of high-sensitivity C-reactive protein to percutaneous coronary intervention in patients with acute coronary syndrome.
Yun K, Jeong M, Oh S, Rhee S, Park E, Lee E
Heart Vessels. 2009; 24(3):175-80.
PMID: 19466517
DOI: 10.1007/s00380-008-1110-5.
Effects of drug-eluting stents on systemic inflammatory response in patients with unstable angina pectoris undergoing percutaneous coronary intervention.
Ozer N, Tangurek B, Firat F, Ozer S, Tartan Z, Ozturk R
Heart Vessels. 2008; 23(2):75-82.
PMID: 18389330
DOI: 10.1007/s00380-007-1020-y.
Does the use of paclitaxel or rapamycin-eluting stent decrease further need for coronary-artery bypass grafting when compared with bare-metal stent?.
Lemos Jr H, Atallah A
Sao Paulo Med J. 2007; 125(4):242-5.
PMID: 17992397
PMC: 11020538.
DOI: 10.1590/s1516-31802007000400010.
Osteoprotegerin is not associated with angiographic coronary calcification.
Gogo Jr P, Schneider D, Terrien E, Sobel B, Dauerman H
J Thromb Thrombolysis. 2006; 22(3):177-83.
PMID: 17111200
DOI: 10.1007/s11239-006-9026-3.
The effects of prior beta-blocker therapy on serum C-reactive protein levels after percutaneous coronary intervention.
Atar I, Gulmez O, Atar A, Bozbas H, Yildirir A, Ozin B
Clin Cardiol. 2005; 28(5):243-6.
PMID: 15971460
PMC: 6654617.
DOI: 10.1002/clc.4960280509.
Associations between C-reactive protein and circulating cell adhesion molecules in patients with unstable angina undergoing coronary intervention and their clinical implication.
Doo Y, Han S, Park W, Kim S, Choi S, Cho G
Clin Cardiol. 2005; 28(1):47-51.
PMID: 15704532
PMC: 6654017.
DOI: 10.1002/clc.4960280112.
Inflammation as a mechanism and therapeutic target for in-stent restenosis.
Drachman D, Simon D
Curr Atheroscler Rep. 2005; 7(1):44-9.
PMID: 15683602
DOI: 10.1007/s11883-005-0074-5.
Evidence for C-reactive protein's role in (CRP) vascular disease: atherothrombosis, immuno-regulation and CRP.
Mazer S, Rabbani L
J Thromb Thrombolysis. 2004; 17(2):95-105.
PMID: 15306744
DOI: 10.1023/B:THRO.0000037664.77460.d8.
Relation between C reactive protein concentrations and coronary microvascular endothelial function.
Teragawa H, Fukuda Y, Matsuda K, Ueda K, Higashi Y, Oshima T
Heart. 2004; 90(7):750-4.
PMID: 15201242
PMC: 1768328.
DOI: 10.1136/hrt.2003.022269.
C-reactive protein plasma levels but not factor VII activity predict clinical outcome in patients undergoing elective coronary intervention.
Grander W, Dichtl W, Prokop W, Roithinger F, Moes N, Friedrich G
Clin Cardiol. 2004; 27(4):211-6.
PMID: 15119695
PMC: 6653851.
DOI: 10.1002/clc.4960270407.